-transparent.png){kind=logo}
Our studies in human epidermal keratinocytes as a model system have suggested that the antibiotic topoisomerase II inhibitors, novobiocin and nalidixic acid, may be of value for the treatment of hyperproliferative skin disorders. We have therefore conducted a pilot study of the clinical efficacy of these compounds for the treatment of psoriasis. The compounds were administered topically to psoriatic plaques in seven healthy patients over a period of 6 weeks. Nalidixic acid (2%) or novobiocin (2% or 5%) in methylcellulose were applied twice daily under occlusion, and methylcellulose alone was used as a control. In six of the seven patients, one or both compounds effected somewhat greater improvement than in the control within 3 weeks of treatment.
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
January 1989,
Zeitschrift fur Naturforschung. C, Journal of biosciences,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
September 1980,
Mutation research,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
July 1986,
The Journal of biological chemistry,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
September 1980,
Biochemical and biophysical research communications,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
January 1978,
Nature,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
February 2018,
European journal of dermatology : EJD,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
February 1973,
Archives of dermatology,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
October 1983,
The Journal of general virology,
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
July 1981,
Science (New York, N.Y.),
V A Bohr, and
E A Abel, and
E M Farber, and
P C Hanawalt
January 1999,
Pediatric dermatology,
